AstraZeneca Capitalizing On Respiratory With Actavis’ Divestiture
This article was originally published in The Pink Sheet Daily
Executive Summary
The British pharma is acquiring Actavis’ unwanted respiratory portfolio in a deal that will help AstraZeneca meet the $8 billion in revenues it expects to achieve from its respiratory franchise by 2023. For Actavis, it means unloading a handful of drugs that were underperforming and neglected.